E
Cyclacel Pharmaceuticals, Inc. CYCC
$0.354 $0.055118.43% NASDAQ
Recommendation
Prev Close
$0.2989
Volume
3,033,337
Avg Vol (90D)
3,158,076
Market Cap
$61.97M
Dividend & Yield
--
52-Week Range
$0.1706 - $3.08
P/E (TTM)
--
EPS (TTM)
-$5.31
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Cyclacel Pharmaceuticals (CYCC) Plans Strategic Acquisition and Rebranding CYCC Stock News
5/6/2025 - GuruFocus
Cyclacel Pharmaceuticals enters exchange agreement with Fitters
5/6/2025 - The Fly
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS ...
5/6/2025 - GuruFocus
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS ...
5/6/2025 - GuruFocus
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE
5/6/2025 - Globe Newswire
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com
5/4/2025 - MarketBeat
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com
5/3/2025 - Ticker Report
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Update
4/30/2025 - MarketBeat
Video: Tuesday Sector Leaders: Cigarettes & Tobacco, Drugs
4/29/2025 - Market News Video
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com
4/27/2025 - Ticker Report
Cyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holders
4/25/2025 - TipRanks Financial Blog
Cyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holders
4/25/2025 - The Fly
Cyclacel Pharmaceuticals (CYCC) Announces Quarterly Dividend
4/25/2025 - GuruFocus
Cyclacel Pharmaceuticals declares $0.15 dividend
4/25/2025 - SeekingAlpha.com: All News
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
4/3/2025 - Ticker Report
Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development
4/3/2025 - TipRanks Financial Blog
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
4/2/2025 - GuruFocus
Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift
4/2/2025 - TipRanks Financial Blog
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
4/2/2025 - Globe Newswire
cyclacel pharmaceuticals sheds clinical cancer asset effort stop cash spiral
4/2/2025 - FierceBiotech.com - Biotech
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com
4/2/2025 - Ticker Report
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible ...
3/24/2025 - GuruFocus
Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement
3/24/2025 - Seeking Alpha - Healthcare
Cyclacel announces $1M private placement of convertible preferred stock
3/24/2025 - TipRanks Financial Blog
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
3/24/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$43.00K
EBITDA (TTM)
-$12.00M
EBIT (TTM)
-$12.00M
Net Income (TTM)
-$11.21M
Balance Sheet
Total Assets (Q)
$4.09M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$6.27M
Book Value Per Share (Q)
-$0.2454
Cash Flow
Cash from Operations (TTM)
-$7.99M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$7.82M
Net Change in Cash (TTM)
-$241.00K
Filings
Filing Date
Wednesday, April 2, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.34
7-Day Total Return
27.11%
30-Day Total Return
9.26%
60-Day Total Return
12.03%
90-Day Total Return
8.79%
Year to Date Total Return
-4.56%
1-Year Total Return
-82.90%
2-Year Total Return
-95.70%
3-Year Total Return
-98.65%
5-Year Total Return
-99.42%
52-week Low
Apr 07, 2025 - $0.1706
52-week High
May 31, 2024 - $3.08
Valuation
Market Cap
$61.97M - Micro Cap
Enterprise Value
$58.84M
Price/Sales (TTM)
64.98
Price/Book (Q)
-1.22
Dividends and Shares
Shares Outstanding
9.24M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.cyclacel.com
Phone Number
60 9 08517 7330
Address
Tower 11
Level 10, Avenue 5, No. 8 - Jalan Kerinchi
Kuala Lumpur, 59200
Country
Malaysia
Year Founded
1996
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United... more
NASDAQ 05/06/2025 4:00PM Eastern Quotes delayed